Guggenheim raised the firm’s price target on Neurocrine to $164 from $157 and keeps a Buy rating on the shares as Ingrezza Q4 sales came in largely in line with the firm’s and consensus estimates. Key highlights from the print include Neurocrine’s plans to file to FDA for Crinecerfont approval in CAH in Q2, the company preparing for crinecerfont’s launch in 2025 and the company providing 2024 net product sales guidance of $2.1-2.2B, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NBIX:
- Neurocrine price target raised to $161 from $160 at Deutsche Bank
- Neurocrine price target raised to $106 from $100 at Piper Sandler
- Neurocrine price target raised to $154 from $150 at Canaccord
- Neurocrine price target raised to $140 from $116 at Mizuho
- Neurocrine price target raised to $140 from $127 at Wells Fargo